SGLT2 Inhibitors and Survival in Lung Cancer Patients With Diabetes
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: SGLT-2 inhibitor, Sham (No Treatment).
- Who it may be relevant to
- Registry conditions: Lung Cancer. Basic parameters: No limits · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Center list to be confirmed — check the primary protocol.
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
The Impact of SGLT2i on the Outcome of Advanced Lung Cancer in Patients With Diabetes
Overview
The goal of this clinical trial The goal of this clinical trial is to evaluate whether SGLT2 inhibitor drugs can extend overall survival or delay the progression of the tumor in patients with both advanced lung cancer and diabetes. It will also check if these drugs are safe for these patients. The main questions it aims to answer are: * Does adding an SGLT2 inhibitor to standard cancer treatment improve survival? * Does it cause more or fewer cardiovascular toxicity? * What side effects do participants experience? Researchers will compare a group taking an SGLT2 inhibitor to a group not taking SGLT2 inhibitor to see if the drug works. Participants will: * Be adults diagnosed with advanced lung cancer and type 2 diabetes. * Take either the SGLT2 inhibitor pill or other hypoglycemic drugs once a day alongside their cancer treatment. * Undergo regular clinical visits for monitoring, laboratory tests, and imaging studies
Interventions
- Drug SGLT-2 inhibitor
SGLT2 inhibitors used for patients with lung cancer and diabetes - Other Sham (No Treatment)
SGLT2 inhibitors are not used for patients with lung cancer and diabetes
Primary outcome measures
- Number of Participants with death [Time frame: From enrollment to the end of treatment at 12 months]
Secondary outcome measures (1)
- Number of Participants with new-onset atrial fibrillation/flutter, acute coronary syndrome, myocarditis, massive pericardial effusion, heart failure and third-degree atrioventricular block. [Time frame: From enrollment to the end of treatment at 12 months]
Eligibility criteria
Inclusion criteria
- Lung cancer patients receiving standard anti-tumor treatment; type 2 diabetes; patients with a score of 0-2 assessed by Eastern Cooperative Oncology Group's performance status; the patients agreed to participate in this study.
Exclusion criteria
- Severe abnormalities in liver, kidney or heart functions; expected lifespan less than 3 months.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Open label
- Primary purpose
- Treatment
Study locations
Center list to be confirmed — check the primary protocol.
Identifiers
NCT: NCT07272057 · SLC-DO